← Back to Search

HPV Vaccine Strategies for Human Papillomavirus (HPVV Trial)

N/A

Recruiting

Led By Erin Hahn, PhD

Research Sponsored by Kaiser Permanente

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up year 1 through year 4

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing whether a tailored or prescribed HPV vaccine intervention can improve provider recommendations and HPV vaccination rates.

Who is the study for?

This trial is for pediatric clinics, their staff including physicians, nurses, and administrators, as well as parents of children aged 9-12 eligible for the HPV vaccine. It excludes healthcare workers outside pediatrics and parents of children over 12 or without a clinic visit in the study period.

What is being tested?

The trial compares three strategies to improve HPV vaccination rates: a 'local-tailored' strategy addressing local barriers; a 'prescribed' strategy targeting pre-selected barriers; and usual care with no research-led activities.

What are the potential side effects?

Since this study focuses on implementation strategies rather than medical treatments, it does not directly involve side effects from interventions like drugs or vaccines.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ year 1 through year 4

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~year 1 through year 4

This trial's timeline: 3 weeks for screening, Varies for treatment, and year 1 through year 4 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Proportion of children 9-12 years old who received the first dose of the HPV vaccine - EMR

Proportion of children 9-12 years old who received the first dose of the HPV vaccine -EMR

Secondary study objectives

Provider Recommendation - survey

Other study objectives

Fidelity - survey

HPV vaccine series completion - EMR

Parent satisfaction with HPV vaccine communication - survey

+3 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Prescribed StrategyExperimental Treatment1 Intervention

The intervention arm will include 20 clinics randomly assigned to the intervention arm.. All physicians, nurses, department administrator,s and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.

Group II: Local TailoringExperimental Treatment1 Intervention

The intervention arm will include 20 clinics randomly assigned to the intervention arm. All physicians, nurses, department administrator and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.

Group III: Usual CareActive Control1 Intervention

The intervention arm will include 20 clinics randomly assigned to the usual care arm. All physicians, nurses, department administrators,s and other staff members from the pediatric departments randomized to this arm will be included in the study, as well as parents of HPV vaccine eligible children (9-12 years old) who had one or more visits with their pediatric provider during the data collection period.

Do I qualify?Apply below to find out